Key result
Mavacamten significantly improves exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy compared to placebo.
Why the study?
Targeting hypercontractility with cardiac myosin inhibitors has introduced disease-specific therapy for HCM, warranting a review of their mechanistic basis and clinical evidence.
Do cardiac myosin inhibitors improve symptoms and reduce left ventricular outflow tract gradients in patients with hypertrophic cardiomyopathy?
Do cardiac myosin inhibitors improve symptoms and reduce left ventricular outflow tract gradients in patients with hypertrophic cardiomyopathy?
Cardiac myosin inhibitors represent the first disease-specific pharmacological therapy for hypertrophic cardiomyopathy, effectively reducing LVOT gradients and improving symptoms by targeting sarcomeric hypercontractility.
Answers are grounded in this paper and cite their sources.
Supports myosin inhibition for obstructive HCM symptoms; leaves open long-term outcomes and non-obstructive applications.
Hypertrophic cardiomyopathy (HCM) represents the most common inherited cardiac disease and a leading cause of heart failure, arrhythmias, and sudden cardiac death in young individuals. For decades, management of HCM has relied on symptom control with β-blockers, calcium channel blockers, disopyramide, or invasive septal reduction in advanced cases. The identification of pathogenic sarcomere variants and the recognition of hypercontractility as a central disease mechanism have paved the way for cardiac myosin inhibitors (CMIs), the first truly disease-specific pharmacological therapy for HCM. Indeed, CMIs represent a revolutionary therapeutic paradigm that redefines the standard of care by translating molecular discovery into clinical application. This review provides a guide to the mechanistic basis of sarcomere modulation, summarizes the clinical evidence for mavacamten and aficamten, and critically evaluates the evolving roles of both medications in obstructive and non-obstructive HCM.
No takes yet. Share an insight, caveat, or question.
Sedaghat-Hamedani et al. (2026) conducted a review in Hypertrophic Cardiomyopathy. Mavacamten vs. Placebo was evaluated on Exercise capacity and symptoms improvement (OR 2.5). Mavacamten significantly improves exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: